A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 401–500 of 709
DeLeon, O., Hodis, H., O’Malley, Y., Johnson, J., Salimi, H., Zhai, Y., Winter, E., Remec, C., Eichelberger, N., Cleave, B. V., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001549 · Cited by 21
Verkoczy, L. K. (2017) · Advances in immunology · doi:10.1016/bs.ai.2017.01.004 · Cited by 21
“In particular, PGT121 has LCs with a 3 aa insertion in framework 3 (LFR3), and PGT128 has a 6 aa insertion in its HCDR2; both events appear important for neutralization breadth/potency (Doores et al., 2015; Pejchal et al., 2011; Sok et al., 2013).”
Wen, Y., Trinh, H. V., Linton, C. E., Tani, C., Norais, N., Martinez-Guzman, D., Ramesh, P., Sun, Y., Situ, F., Karaca-Griffin, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194266 · Cited by 19
Antibody Neutralization of HIV-1 Crossing the Blood-Brain Barrier
Lorin, V., Danckaert, A., Porrot, F., Schwartz, O., Afonso, P. V., & Mouquet, H. (2020) · mBio · doi:10.1128/mbio.02424-20 · Cited by 19
Carbonetti, S., Oliver, B. G. G., Glenn, J. A., Stamatatos, L., & Sather, D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086905 · Cited by 18
Targeting the N332-supersite of the HIV-1 envelope for vaccine design
Moyo-Gwete, T., Kitchin, D., & Moore, P. L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1752183 · Cited by 18
“The CDRH3 loops of the PGT125-PGT131 lineage also penetrate the glycan shield and target the (324)GDIR(327) motif, but differ from PGT121-123 in that interactions with these residues are mediated through backbone hydrogen bonding and van der Waals interactions [54].”
BackgroundBraddom, A. E., Bol, S. M., Gonzales, S. J., Reyes, R. A., Musinguzi, K., Nankya, F., Ssewanyana, I., Greenhouse, B., & Bunnik, E. M. (2021) · mSphere · doi:10.1128/msphere.00726-21 · Cited by 21
“For example, broadly neutralizing antibodies against HIV often have long HCDR3 regions that are thought to contribute to the recognition of structurally occluded epitopes on viral proteins (27, 39, 40).”
BackgroundZhou, J., Wang, L., Liu, X., Gai, Y., Dong, M., Wang, C., Ali, M. M., Ye, M., Yu, X., & Hu, L. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c00142 · Cited by 18
Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies
Qi, Y., Jo, S., & Im, W. (2015) · Glycobiology · doi:10.1093/glycob/cwv101 · Cited by 19
Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
Geiß, Y., & Dietrich, U. (2015) · PubMed · Cited by 24
2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies
Doores, K. J., Huber, M., Le, K. M., Wang, S., Doyle-Cooper, C., Cooper, A. B., Pantophlet, R. A., Wong, C., Nemazee, D. A., & Burton, D. R. (2012) · Journal of Virology · doi:10.1128/jvi.02820-12 · Cited by 18
“(3, 4), 2G12 has been shown to bind glycans alone.”
BackgroundSelf-citationEngineering broadly neutralizing antibodies for HIV prevention and therapy
Hua, C. K., & Ackerman, M. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.013 · Cited by 18
Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production
O’Rourke, S. M., Byrne, G., Tatsuno, G. P., Wright, M., Yu, B., Mesa, K. A., Doran, R. C., Alexander, D. L., & Berman, P. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197656 · Cited by 18
Detection and isolation of auto-reactive human antibodies from primary B cells
Sendra, V. G., Lie, A., Romain, G., Agarwal, S. K., & Varadarajan, N. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.018 · Cited by 17
Antibody‐mediated control mechanisms of viral infections
Mackin, S., Sariol, A., & Diamond, M. (2024) · Immunological Reviews · doi:10.1111/imr.13383 · Cited by 17
“51,52 (d) antibody-induced aggregation of virions which reduces the effective number of infectious particles and has been described for poliovirus, alpha-viruses, orthoflaviviruses, and influenza virus.”
Narayan, K. M., Agrawal, N., Du, S. X., Muranaka, J., Bauer, K., Leaman, D. P., Phung, P., Limoli, K. L., Chen, H., Boenig, R. I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052732 · Cited by 17
Mikell, I., & Stamatatos, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049610 · Cited by 17
“These two glycans are part of the epitopes of the PGTlike antibodies [37,38].”
BackgroundTsuchiya, K., Ode, H., Hayashida, T., Kakizawa, J., Sato, H., Oka, S., & Gatanaga, H. (2013) · Scientific Reports · doi:10.1038/srep02389 · Cited by 18
Han, S. Y., Antoine, A., Howard, D., Chang, B., Chang, W. S., Slein, M. D., Deikus, G. Y., Κοσσίδα, Σ., Duroux, P., Lefranc, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00329 · Cited by 17
Doran, R. C., Tatsuno, G. P., O’Rourke, S. M., Yu, B., Alexander, D. L., Mesa, K. A., & Berman, P. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196370 · Cited by 17
Li, S. W., Wright, M., Healey, J. F., Hutchinson, J. M., O’Rourke, S. M., Mesa, K. A., Lollar, P., & Berman, P. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233866 · Cited by 17
HIV-1 Envelope Glycosylation and the Signal Peptide
Lambert, G. S., & Upadhyay, C. (2021) · Vaccines · doi:10.3390/vaccines9020176 · Cited by 18
“As these variable regions are commonly targeted by nAbs, their shortening presents fewer potential targets for the immune system [91-93].”
BackgroundHost–pathogen interaction in HIV infection
Chowdhury, A., & Silvestri, G. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.07.003 · Cited by 20
The Janus Face of Follicular T Helper Cells in Chronic Viral Infections
Greczmiel, U., & Oxenius, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01162 · Cited by 19
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
Gieselmann, L., DeLaitsch, A. T., Rohde, M., Gruell, H., Kreer, C., Ercanoglu, M. S., Gristick, H. B., Schommers, P., Ahmadov, E., Radford, C. E., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02286-5 · Cited by 17
Perspectives in Glycomics and Lectin Engineering
Tkáč, J., Bertók, T., Nahálka, J., & Gemeiner, P. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1292-6_37 · Cited by 17
““neutralisation” of various forms of viruses (17,18) or more efficient vaccines against various diseases (19, 20).”
BackgroundAntibodies expose multiple weaknesses in the glycan shield of HIV
Crispin, M., & Bowden, T. A. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2627 · Cited by 16
Self-citationBeretta, M., Moreau, A., Bouvin-Pley, M., Essat, A., Goujard, C., Chaix, M., Hué, S., Meyer, L., Barin, F., & Braibant, M. (2018) · AIDS · doi:10.1097/qad.0000000000001906 · Cited by 16
Trattnig, N., Mayrhofer, P., Kunert, R., Mach, L., Pantophlet, R. A., & Kosma, P. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00731 · Cited by 16
Frank, I., Cigoli, M. S., Arif, M. S., Fahlberg, M. D., Maldonado, S., Calenda, G., Pegu, A., Yang, E. S., Rawi, R., Chuang, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7201 · Cited by 16
Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
Rujas, E., Cui, H., Burnie, J., Aschner, C. B., Zhao, T., Insausti, S., Muthuraman, K., Semesi, A., Ophel, J., Nieva, J. L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112887119 · Cited by 16
Self-citationBudhadev, D., Hooper, J., Rocha, C., Nehlmeier, I., Kempf, A., Hoffmann, M., Krüger, N., Zhou, D.-J., Pöhlmann, S., & Guo, Y. (2023) · JACS Au · doi:10.1021/jacsau.3c00163 · Cited by 11
Magnus, C., Reh, L., & Trkola, A. (2015) · Virus Research · doi:10.1016/j.virusres.2015.10.009 · Cited by 17
“Resistance in BG505 is inferred by loss of the N-glycosylation site at amino acid position 332 which is crucial for several bnAbs including PGT121, PGT128 and 2G12 (Sanders et al., 2002; Scanlan et al., 2002; Calarese et al., 2003; Pejchal et al., 2011; Julien et al., 2013; Sok et al., 2014).”
Backgroundde Geus, E. D., Tefsen, B., van Haarlem, D. A., van Eden, W., van Die, I., & Vervelde, L. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.007 · Cited by 16
Native functionality and therapeutic targeting of arenaviral glycoproteins
Crispin, M., Zeltina, A., Zitzmann, N., & Bowden, T. A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.04.001 · Cited by 16
Self-citationBalasubramanian, P., Kumar, R., Williams, C. A. U., Itri, V., Wang, S., Lu, S., Hessell, A. J., Haigwood, N. L., Sinangil, F., Higgins, K. W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.107 · Cited by 16
Self-citationGrant, O. C. (2021) · ModelArchive SIB · doi:10.5452/ma-zykoq · Cited by 16
Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design
Skelly, A. N., Gristick, H. B., Li, H. J., Gavor, E., Connell, A. J., Kreider, E. F., Marchitto, L., Hogarty, M. P., Newby, M. L., Allen, J. D., et al. (2026) · Science · doi:10.1126/science.aec6396 · Cited by 16
Self-citationBai, H., Lewitus, É., Li, Y., Thomas, P. V., Zemil, M., Merbah, M., Peterson, C. E., Thuraisamy, T., Rees, P. A., Hajduczki, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48139-x · Cited by 15
Immunogen design to focus the B-cell repertoire
Sattentau, Q. J. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000054 · Cited by 16
“However, if the antigenic complexity of the entire gp140 trimer fails to boost the desired responses, then increased focusing may be obtained using engineered peptide or glycopeptide mimetics of specific antigenic regions of Env, such has been demonstrated for the quaternary PG9 [29,62–64] and ‘supersite of vulnerabil…”
BackgroundInfluentialWang, Z., Lorin, C., Koutsoukos, M., Franco, D., Bayat, B., Zhang, Y., Carfí, A., Barnett, S. W., & Porter, F. (2016) · Vaccines · doi:10.3390/vaccines4020017 · Cited by 15
“The dataset also confirmed the presence in both molecules of high mannose glycan clusters around the C2-V3-C3-V4-C4 domains, which are known as epitopes for bNAb 2G12 [6] and a partial epitope for PGT128 [7].”
BackgroundMoshoette, T., Ali, S. A., Papathanasopoulos, M. A., & Killick, M. A. (2019) · Retrovirology · doi:10.1186/s12977-019-0493-y · Cited by 16
Donahue, T. C., Zong, G., O'Brien, N. A., Ou, C., Gildersleeve, J. C., & Wang, L. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00211 · Cited by 16
Contribution of VH replacement products to the generation of anti-HIV antibodies
Liao, H., Guo, J.-T., Lange, M. D., Fan, R., Zemlin, M., Su, K., Guan, Y., & Zhang, Z. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.11.003 · Cited by 15
“For the PGT type of antibodies, it has been shown that most of them have very long CDR3 regions, which are essential for penetration of the sugar glycan shield on gp120 [7, 8].”
BackgroundInfluentialClosing the door to human immunodeficiency virus
Kang, Y., Guo, J., & Chen, Z. (2013) · Protein & Cell · doi:10.1007/s13238-012-2111-9 · Cited by 16
“PGT128, the broadest Nab among this class, interacts with a conserved site of V3 and two glycans of the gp120 subunit, which determines its high binding affinity and wide-ranging specificity (Pejchal et al., 2011).”
BackgroundMabvakure, B. M., Scheepers, C., Garrett, N., Karim, S. S. A., Williamson, C. E., Morris, L., & Moore, P. L. (2018) · Journal of Virology · doi:10.1128/jvi.01685-18 · Cited by 16
Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design
McGuire, A. T. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000548 · Cited by 16
Wang, S., Voronin, Y., Zhao, P., Ishihara, M., Mehta, N., Porterfield, M., Chen, Y., Bartley, C., Hu, G., Han, D. G., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01968-19 · Cited by 15
“The PGT128 epitopes includes glycans at positions 332 and 301, as well as the C-terminal end of the V3 loop (18).”
BackgroundMethodInfluentialSelf-citationJohnson, J., Flores, M. G., Rosa, J., Han, C., Salvi, A. M., DeMali, K. A., Jagnow, J., Sparks, A. E., & Haim, H. (2020) · Journal of Virology · doi:10.1128/jvi.01749-19 · Cited by 16
“The International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium kindly provided MAbs PGT121 and PGT126 (14, 105).”
BackgroundEnhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells
Anand, S. P., Ding, S., Tolbert, W. D., Prévost, J., Richard, J., Gil, H. M., Gendron‐Lepage, G., Cheung, W.-F., Wang, H., Pastora, R., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00796-21 · Cited by 16
Self-citationStamatatos, L. (2025) · Current HIV Research · doi:10.2174/011570162x358302250206074255 · Cited by 16
“…located within the receptor binding site CD4-BS [56-58], the apex of the Env tri-mer [59-64], an area around the conserved N332 glycan site in V3 [65-71], a cluster of mannose residues on gp120 [26, 72-74], the fusion peptide of the gp41 subunit [75], the extra-cellular part of the transmembrane…”
Nie, J., Wang, W., Wen, Z., Song, A., Hong, K., Lu, S., Zhong, P., Xu, J., Kong, W., Li, J., et al. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.07.011 · Cited by 14
Candidate Antibody-Based Therapeutics Against HIV-1
Gong, R., Chen, W., & Dimitrov, D. S. (2012) · BioDrugs · doi:10.2165/11631400-000000000-00000 · Cited by 14
Kesavardhana, S., Das, R., Citron, M. P., Datta, R., Ecto, L. T., Srilatha, N. S., DiStefano, D. J., Swoyer, R., Joyce, J. G., Dutta, S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.725614 · Cited by 14
“We also individually mutated glycan sites in the V1V2 region (N156K and N160K) that are essential for binding of V1V2 quaternary epitope-specific bNAbs (51), and we mutated a glycan position at the base of the V3 loop region (N332T) essential for binding of V3 glycan-specific bNAbs (40, 41).”
BackgroundImpact of glycosylation on viral vaccines
Lembo, A., Molinaro, A., Castro, C. D., Berti, F., & Biagini, M. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122402 · Cited by 14
Passive Immunization against HIV/AIDS by Antibody Gene Transfer
Yang, L., & Wang, P. (2014) · Viruses · doi:10.3390/v6020428 · Cited by 16
“Building upon their previous work [95], Burton and coworkers screened memory B cells from four elite neutralizers and identified several glycan-dependent bnAbs, designated PGT121-PGT145 [101], some of which can penetrate the glycan shield and recognize an epitope in the vicinity of the V3 loop region, as well as two c…”
BackgroundO’Rourke, S. M., Sutthent, R., Phung, P., Mesa, K. A., Frigon, N. L., To, B., Horthongkham, N., Limoli, K. L., Wrin, T., & Berman, P. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119608 · Cited by 14
“Subsequently, it was reported that the PGT128 family of bNAbs depended on contacts with glycans at N136 in the V1 domain and at N301 and N332 in the stem of the V3 domain [18,21,24].”
BackgroundBanerjee, S., Shi, H., Banasik, M., Moon, H.-J., Lees, W., Qin, Y., Harley, A., Shepherd, A. J., & Cho, M. W. (2017) · Virology · doi:10.1016/j.virol.2017.02.015 · Cited by 14
“…of human monoclonal antibodies (mAbs) have been isolated from virus-infected patients that can neutralize a large number of HIV-1 variants from multiple clades (Huang et al., 2014, 2012; Pejchal et al., 2011; Scheid et al., 2011; Walker et al., 2011, 2009; Wu et al., 2010; Zwick et al., 2001).”
BackgroundPreventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1
Jaworski, J. P., & Cahn, P. E. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30174-7 · Cited by 15
Dotsey, E. Y., Gorlani, A., Ingale, S., Achenbach, C. J., Forthal, D. N., Felgner, P. L., & Gach, J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125581 · Cited by 14
Wang, H., Yuan, T., Li, T., Li, Y., Feng, Q., Zhu, C., Liang, S., Hoffmann, D. E., Dittmer, U., Sun, B., et al. (2018) · Archives of Virology · doi:10.1007/s00705-018-4011-7 · Cited by 14
Ma, X., Allahou, L. W., Yang, R., Ma, Y., Dimoula, M., Chau, D. Y. S., Williams, G. R., Knowles, J. C., & Poma, A. (2025) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2025.101099 · Cited by 14
Chenine, A.-L., Wieczorek, L., Sanders‐Buell, E., Wesberry, M., Towle, T., Pillis, D. M., Molnar, S., McLinden, R., Edmonds, T. G., Hirsch, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076104 · Cited by 13
Bowles, E. J., Schiffner, T., Rosario, M., Needham, G. A., Ramaswamy, M., McGouran, J. F., Kessler, B. M., LaBranche, C. C., McMichael, A. J., Montefiori, D. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114709 · Cited by 13
Pentiah, K., Lees, W., Moss, D. S., & Shepherd, A. J. (2014) · Glycobiology · doi:10.1093/glycob/cwu097 · Cited by 13
“Yet the density of glycans on HA is much less than that on some other well-known viral glycoproteins, such as the HIVenvelope protein gp120, which has a “dense glycan shield” (Pejchal et al. 2011).”
BackgroundNeutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
Jaworski, J. P., Alejandrina, V., & Chiavenna, S. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00661 · Cited by 13
Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies
Wei, Q., Hargett, A. A., Knoppová, B., Duverger, A. E., Rawi, R., Shen, C., Farney, S. K., Hall, S. D., Brown, R., Keele, B. F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101711 · Cited by 13
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
Miller, N. L., Raman, R., Clark, T., & Sasisekharan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904609 · Cited by 13
Feasibility of Brewer’s Spent Yeast Microcapsules as Targeted Oral Carriers
Reis, S. F., Martins, V. J., Bastos, R., Lima, T., Correia, V. G., Pinheiro, B., Silva, L. M., Palma, A. S., Ferreira, P., Vilanova, M., et al. (2023) · Foods · doi:10.3390/foods12020246 · Cited by 13
Evolving roles of glycosylation in the tug-of-war between virus and host
Zhai, X., Yuan, Y., He, W., Wu, Y. C., Shi, Y., Su, S., Du, Q., & Mao, Y. (2024) · National Science Review · doi:10.1093/nsr/nwae086 · Cited by 13
Recent advances in the metallo-glycodendrimers and its potential applications
Khan, S. A., Adak, A., Murthy, R. V., & Kikkeri, R. V. (2013) · Inorganica Chimica Acta · doi:10.1016/j.ica.2013.06.017 · Cited by 13
Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines
Wang, Z., Qin, C., Jing Hua, H. U., Guo, X., & Yin, J. (2016) · Virologica Sinica · doi:10.1007/s12250-015-3691-3 · Cited by 13
Moyo-Gwete, T., Ferreira, R.-C., Davids, R., Sonday, Z., Moore, P. L., Travers, S. A. A., Wood, N. T., & Dorfman, J. R. (2016) · Virology · doi:10.1016/j.virol.2016.10.026 · Cited by 13
Kosztyu, P., Kuchař, M., Černý, J., Barkocziova, L., Maly, M., Petroková, H., Czerneková, L., Lišková, V., Kafkova, L. R., Knötigová, P. T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.015 · Cited by 13
The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans
Nguyen, D. N. P., Redman, R. L., Horiya, S., Bailey, J. K., Xu, B., Stanfield, R. L., Temme, J. S., LaBranche, C. C., Wang, S., Rodal, A. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00053 · Cited by 13
Self-citationGeneral Strategies for Glycan Microarray Data Processing and Analysis
Temme, J. S., & Gildersleeve, J. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2148-6_5 · Cited by 13
Khan, L., Makhdoomi, M. A., Kumar, S., Nair, A., Andrabi, R., Clark, B. E., Auyeung, K., Bhattacharya, J., Vajpayee, M., Wig, N., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125575 · Cited by 13
Sadjadpour, R., Donau, O. K., Shingai, M., Buckler-White, A. J., Kao, S., Strebel, K., Nishimura, Y., & Martin, M. A. (2013) · Journal of Virology · doi:10.1128/jvi.00878-13 · Cited by 13
“Crystal structures of PGT121 and PGT128 antigen binding domains interacting with HIV-1 JR-FL and HIV-1 YU-2 gp120 molecules, respectively, have revealed that both neutralizing MAbs bind to epitopes associated with the N332 glycan and amino acids located at the base of the V3 loop (27, 28).”
BackgroundKumar, R., Pan, R., Upadhyay, C., Mayr, L. M., Cohen, S., Wang, X.-H., Balasubramanian, P., Nadas, A. J., Seaman, M. S., Zolla‐Pazner, S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01280-15 · Cited by 12
Kubota, Y., Hori, H., Sawa, R., Seki, H., & Uzawa, J. (2012) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.3859 · Cited by 12
Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies
Pfeifer, N., Walter, H., & Lengauer, T. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000283 · Cited by 12
“It has been shown that the highly potent PGTneutralizing antibodies interact with V3 sites 323, 324, 325, and 327 as well as N-linked glycans at position 301 and/or 332.(17,18) Thus, these antibodies might also exhibit stronger neutralization capabilities against R5 viruses than against X4-capable viruses.”
BackgroundSynthesis of high-mannose 1-thio glycans and their conjugation to protein
Bailey, J. J., & Bundle, D. R. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42194e · Cited by 12
Hicar, M. D., Chen, X., Kalams, S. A., Sojar, H. T., Landucci, G., Forthal, D. N., Spearman, P. W., & Crowe, J. E. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.12.002 · Cited by 12
“Since long Ab HCDR3s have been proposed to be enriched in populations of HIV neutralizing Abs [35], we evaluated the heavy chain complementarity determining region 3 (HCDR3) length distribution within our clones.”
BackgroundHIV-1 Consensus Envelope-Induced Broadly Binding Antibodies
Meyerhoff, R. R., Scearce, R. M., Ogburn, D. F., Lockwood, B., Pickeral, J., Kuraoka, M., Anasti, K. M., Eudailey, J., Eaton, A., Cooper, M., et al. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0294 · Cited by 13
Scheepers, C., Chowdhury, S., Wright, W. S., Campbell, C. T., Garrett, N., Karim, Q. A., Karim, S. S. A., Moore, P. L., Gildersleeve, J. C., & Morris, L. (2017) · AIDS · doi:10.1097/qad.0000000000001643 · Cited by 12
Han, C., Johnson, J., Dong, R., Kandula, R., Kort, A. J., Wong, M., Yang, T., Breheny, P. J., Brown, G., & Haim, H. (2020) · mBio · doi:10.1128/mbio.00126-20 · Cited by 12
“1B) may result from higher resistance of the latter to antibody neutralization (24, 42–44).”
Glycopeptide Mimetics Recapitulate High‐Mannose‐Type Oligosaccharide Binding and Function
Lusvarghi, S., Ghirlando, R., Wong, C., & Bewley, C. A. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500157 · Cited by 12
Self-citationLiu, C., Zheng, X., & Ye, X. (2016) · ChemMedChem · doi:10.1002/cmdc.201500498 · Cited by 12
Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen
Liu, C., Zhai, C., Zheng, X., & Ye, X. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00224 · Cited by 12
Functional and Protective Role of Neutralizing Antibodies (NAbs) Against Viral Infections
Cheedarla, N., & Hanna, L. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816328-3.00007-6 · Cited by 11
Zhang, Y., Yuan, T., Li, J., Zhang, Y., Xu, J., Shao, Y., Chen, Z., & Zhang, M.-Y. (2013) · AIDS · doi:10.1097/qad.0000000000000015 · Cited by 11
“Approximately twelve bnmAbs have been co-crystalized with Env and their neutralizing epitopes determined [18, 20-26].”
BackgroundRinge, R. P., & Bhattacharya, J. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613494534 · Cited by 13
“com 71 a fully glycosylated gp120 outer domain, reveals that the antibody penetrates the glycan shield and recognizes two conserved glycans as well as a short β-strand segment of the gp120 V3 loop, accounting for its high binding affinity and broad specificity [Pejchal et al. 2011].”
BackgroundBroadly neutralizing antibodies for therapy of viral infections
Varadarajan, R., Srinivasan, S., Maity, S., & Ghosh, M. (2016) · Antibody Technology Journal · doi:10.2147/anti.s92190 · Cited by 11
“16 All of these antibodies show a slightly different mode of glycan recognition for gp120 sugars.”
Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies
Sun, M., Li, Y., Zheng, H., & Shao, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00391 · Cited by 11
“Curr Opin HIV AIDS (2009) 4(2):104–11.”
BackgroundRathore, U., Purwar, M., Vignesh, V. S., Das, R., Kumar, A. A., Bhattacharyya, S., Arendt, H. E., DeStefano, J., Wilson, A. J., Parks, C. L., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005006 · Cited by 12
Mohan, T., Berman, Z., Kang, S., & Wang, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-25960-1 · Cited by 11
Hutchinson, J. M., Mesa, K. A., Alexander, D. L., Yu, B., O’Rourke, S. M., Limoli, K. L., Wrin, T., Deeks, S. G., & Berman, P. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01021 · Cited by 11
“When we examined the sensitivity of these Envs to bN-mAbs that recognized glycan-dependent epitopes at the base of the V3 domain (14), we found that all of the clones were sensitive to neutralization by the PGT128 bN-mAb but all of the clones were resistant to neutralization by the PGT121 bN-mAb.”
BackgroundChen, Y., Jin, H., Tang, X., Li, L., Geng, X., Zhu, Y., Chong, H., & He, Y. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2011616 · Cited by 11
Carbohydrate moieties as vaccine candidates: Targeting the sweet spot in the immune response
Taylor, C. E., Cobb, B. A., Rittenhouse‐Olson, K., Paulson, J. C., & Schreiber, J. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.090 · Cited by 11
Self-citationAbu-Shmais, A. A., Guo, L., Khalil, A. M., Leonard, S. E. W., Miller, R. J., Janke, A. K., Vukovich, M. J., Bass, L. E., Suresh, Y. P., Rush, S. A., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102564 · Cited by 13
“Glycan-shield-penetrating antibodies have also been reported that bind to HIV-1 Env 51,52 and hepatitis C E2.”
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.